Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Financial requirements of immunisation programmes in developing countries: a 2004-2014 perspective.

Jean-Michel Peny1, Olivier Gleizes, Jean-Pierre Covilard

  • 1Smart Pharma Consulting, 1 rue Houdart de Lamotte, 75015 Paris, France. jmpeny@smart-pharma.com

Vaccine
|June 28, 2005
PubMed
Summary

Estimating childhood immunization costs in developing nations is crucial. This study projects US$14-17 billion needed for vaccines and related expenses over ten years.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Nosocomial rotavirus infection in European countries: a review of the epidemiology, severity and economic burden of hospital-acquired rotavirus disease.

The Pediatric infectious disease journalยท2006
See all related articles

Area of Science:

  • Public Health
  • Health Economics
  • Vaccinology

Background:

  • Vaccines are vital for global public health, particularly in developing countries, yet spending remains low.
  • Millions of children miss routine immunizations, highlighting the need for increased access and funding.
  • Initiatives like the Global Alliance for Vaccines and Immunization (GAVI) aim for universal childhood immunization.

Purpose of the Study:

  • To forecast the financial resources required for childhood immunization in developing countries between 2004 and 2014.
  • To estimate funding needs for both existing and emerging vaccines prioritized by GAVI.

Main Methods:

  • Developed a methodology to calculate required vaccine doses based on disease data, population, and vaccine introduction timelines.
  • Modeled vaccine pricing, considering manufacturer ROI and market competition.

Related Experiment Videos

  • Estimated non-vaccine costs using case studies for capital and recurrent expenditures.

    • Main Results:

    • Optimal scenario funding needs estimated at approximately US$30 billion over 10 years, with vaccines accounting for US$21 billion.
    • Adjusted for uncertainties, total immunization costs are projected between US$14-17 billion.
    • Vaccine-related costs, including new vaccines, form the largest expenditure category in the adjusted scenario.

    Conclusions:

    • Substantial financial resources are necessary to procure and introduce vaccines in developing countries.
    • Anticipated funding can reduce the time lag for vaccine availability compared to industrialized nations.
    • Adequate funding will stimulate research and development for essential vaccines for the developing world.